Head-to-head evidence
Ciclesonide (XRP1526) vs Lodotra
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
Ciclesonide (XRP1526)
Developed by Sanofi
NCT00174720 · Phase 3 · completed
In this randomized, double-blind, placebo-controlled Phase 3 trial, 708 patients with asthma were randomized to one of several ciclesonide dosing regimens or placebo. Ciclesonide produced significantly greater improvements in lung function (FEV1) than placebo, both averaged over weeks 12-16 and at week 16 alone.
Lodotra · Rayos
Marketed by Amgen
NCT00686335 · Phase 2 · completed
This was a single-group, sequential (not randomized) study with no blinding and no true parallel control arm - patients simply switched from morning to evening dosing of the same drug class, and only 7 of 12 enrolled patients completed both periods for the efficacy analysis. The sponsor describes the study as exploratory with descriptive-only analysis and no statistical hypothesis testing, so despite numbers suggesting fewer nighttime awakenings with the evening formulation, this small, unblinded, uncontrolled design cannot serve as strong evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ciclesonide (XRP1526)'s landscape · Lodotra's landscape